Reata's CKD candidate improves kidney function in IgA nephropathy, diabetes cohorts

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from the IgA nephropathy and chronic kidney disease (CKD) associated with Type I diabetes cohorts of the open-label, U.S. Phase II PHOENIX trial of bardoxolone methyl to treat rare forms of CKD.

In 26 patients with IgA nephropathy, once-daily oral bardoxolone significantly increased mean estimated glomerular filtration rate (eGFR) at week 12 by 8 mL/min/1.73 m² compared with baseline (p<0.0001). In 28 patients with CKD associated with Type I diabetes, bardoxolone significantly increased eGFR at week 12 by 5.5 mL/min/1.73 m² compared with baseline ^(p=0.02)...